Author/Authors :
Parissis، نويسنده , , John T and Adamopoulos، نويسنده , , Stamatis and Antoniades، نويسنده , , Charalambos and Kostakis، نويسنده , , George and Rigas، نويسنده , , Antonios and Kyrzopoulos، نويسنده , , Stamos and Iliodromitis، نويسنده , , Efstathios and Kremastinos، نويسنده , , Dimitrios، نويسنده ,
Abstract :
This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients.
